- Home
- URGN vs SENEB Comparison
URGN vs SENEB Comparison
Compare URGN & SENEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- SENEB
- Stock Information
- Founded
- URGN 2004
- SENEB 1949
- Country
- URGN United States
- SENEB United States
- Employees
- URGN N/A
- SENEB N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- SENEB Packaged Foods
- Sector
- URGN Health Care
- SENEB Consumer Staples
- Exchange
- URGN Nasdaq
- SENEB Nasdaq
- Market Cap
- URGN 830.4M
- SENEB 720.7M
- IPO Year
- URGN 2017
- SENEB N/A
- Fundamental
- Price
- URGN $16.82
- SENEB $113.93
- Analyst Decision
- URGN Strong Buy
- SENEB
- Analyst Count
- URGN 8
- SENEB 0
- Target Price
- URGN $28.50
- SENEB N/A
- AVG Volume (30 Days)
- URGN 1.2M
- SENEB 532.0
- Earning Date
- URGN 11-05-2025
- SENEB 11-05-2025
- Dividend Yield
- URGN N/A
- SENEB N/A
- EPS Growth
- URGN N/A
- SENEB N/A
- EPS
- URGN N/A
- SENEB 6.24
- Revenue
- URGN $94,238,000.00
- SENEB $1,571,618,000.00
- Revenue This Year
- URGN $39.63
- SENEB N/A
- Revenue Next Year
- URGN $111.49
- SENEB N/A
- P/E Ratio
- URGN N/A
- SENEB $17.80
- Revenue Growth
- URGN 10.85
- SENEB 7.30
- 52 Week Low
- URGN $3.42
- SENEB $61.38
- 52 Week High
- URGN $21.71
- SENEB $114.49
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- SENEB 69.99
- Support Level
- URGN $15.86
- SENEB $103.07
- Resistance Level
- URGN $17.43
- SENEB $112.00
- Average True Range (ATR)
- URGN 1.06
- SENEB 0.24
- MACD
- URGN -0.15
- SENEB -0.54
- Stochastic Oscillator
- URGN 23.05
- SENEB 100.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.